Cytodyn INC S-1 registration statements

Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.

OQB
CytoDyn Inc. has filed a registration statement for the resale of up to 278 million shares of common stock and shares underlying warrants.
OQB
CytoDyn Inc. is registering for resale up to 486.6 million shares of its common stock by selling stockholders, as the company continues clinical development of leronlimab for various indications.
OQB
CytoDyn Inc. has filed an S-1 registration statement with the SEC to allow selling stockholders to resell up to 141,019,099 shares of common stock, including shares underlying warrants.